Insider · CIK 0001862147
Alexandra Balcom
cfoofficerdirector
Files at CBIO (CRESCENT BIOPHARMA, INC.), NUVL (Nuvalent, Inc.). First filing Nov 4, 2024, latest Dec 10, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 11
$0 bought, $16M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Nuvalent, Inc. | $782k 7,084 shares | -11% | - | |
| 30Weak | Nuvalent, Inc. | $2.1M 20,729 shares | -25% | - | |
| 0Weak | Nuvalent, Inc. | $144k 1,683 shares | -3% | - | |
| 22Weak | Nuvalent, Inc. | $3.5M 40,000 shares | -49% | - | |
| 17Weak | Nuvalent, Inc. | $1.7M 20,000 shares | -24% | - | |
| 30Weak | Nuvalent, Inc. | $2.3M 27,588 shares | -40% | - | |
| 37Weak | Nuvalent, Inc. | $1.7M 20,000 shares | -30% | - | |
| 32Weak | Nuvalent, Inc. | $1.6M 20,000 shares | -24% | - | |
| 24Weak | Nuvalent, Inc. | $320k 4,016 shares | -6% | - | |
| 31Weak | Nuvalent, Inc. | $958k 10,000 shares | -23% | - | |
| 30Weak | Nuvalent, Inc. | $892k 10,000 shares | -23% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 22, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock | +34,500 | $1.08 | $37k | 89,150 | Dec 23, 2025 |
| Dec 22, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -34,500 | $0.00 | $0 | 161,656 | Dec 23, 2025 |
| Dec 8, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -6,984 | $110.31 | $770k | 54,750 | Dec 10, 2025 |
| Dec 8, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -100 | $111.32 | $11k | 54,650 | Dec 10, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +6,875 | $6.89 | $47k | 68,609 | Nov 19, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +13,125 | $72.35 | $950k | 81,734 | Nov 19, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -3,609 | $93.80 | $339k | 78,125 | Nov 19, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -3,266 | $95.12 | $311k | 74,859 | Nov 19, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -4,496 | $100.58 | $452k | 70,363 | Nov 19, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -3,194 | $102.13 | $326k | 67,169 | Nov 19, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -5,055 | $103.27 | $522k | 62,114 | Nov 19, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -380 | $103.68 | $39k | 61,734 | Nov 19, 2025 |
| Nov 18, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +729 | $72.35 | $53k | 62,463 | Nov 19, 2025 |
| Nov 18, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -220 | $103.61 | $23k | 62,243 | Nov 19, 2025 |
| Nov 18, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -509 | $104.54 | $53k | 61,734 | Nov 19, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,875 | $0.00 | $0 | 29,101 | Nov 19, 2025 |
| Nov 17, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -13,125 | $0.00 | $0 | 34,375 | Nov 19, 2025 |
| Nov 18, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -729 | $0.00 | $0 | 33,646 | Nov 19, 2025 |
| Oct 15, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +1,683 | $18.93 | $32k | 63,417 | Oct 17, 2025 |
| Oct 15, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,683 | $85.57 | $144k | 61,734 | Oct 17, 2025 |
| Oct 15, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,683 | $0.00 | $0 | 28,979 | Oct 17, 2025 |
| Oct 13, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +6,875 | $6.89 | $47k | 68,609 | Oct 15, 2025 |
| Oct 13, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +13,125 | $18.93 | $248k | 81,734 | Oct 15, 2025 |
| Oct 13, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -6,138 | $87.90 | $540k | 75,596 | Oct 15, 2025 |
| Oct 13, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -12,266 | $88.73 | $1.1M | 63,330 | Oct 15, 2025 |
| Oct 13, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,596 | $89.22 | $142k | 61,734 | Oct 15, 2025 |
| Oct 14, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +20,000 | $18.93 | $379k | 81,734 | Oct 15, 2025 |
| Oct 14, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -12,280 | $85.75 | $1.1M | 69,454 | Oct 15, 2025 |
| Oct 14, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -5,820 | $86.63 | $504k | 63,634 | Oct 15, 2025 |
| Oct 14, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,700 | $87.67 | $149k | 61,934 | Oct 15, 2025 |
| Oct 14, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -200 | $88.90 | $18k | 61,734 | Oct 15, 2025 |
| Oct 13, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,875 | $0.00 | $0 | 35,976 | Oct 15, 2025 |
| Oct 13, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -13,125 | $0.00 | $0 | 50,662 | Oct 15, 2025 |
| Oct 14, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 30,662 | Oct 15, 2025 |
| Oct 1, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +16,787 | $6.89 | $116k | 78,521 | Oct 3, 2025 |
| Oct 1, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +3,213 | $18.93 | $61k | 81,734 | Oct 3, 2025 |
| Oct 1, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -19,030 | $85.43 | $1.6M | 62,704 | Oct 3, 2025 |
| Oct 1, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -970 | $86.37 | $84k | 61,734 | Oct 3, 2025 |
| Oct 1, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,787 | $0.00 | $0 | 42,851 | Oct 3, 2025 |
| Oct 1, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,213 | $0.00 | $0 | 63,787 | Oct 3, 2025 |
| Sep 29, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +7,588 | $6.89 | $52k | 69,322 | Oct 1, 2025 |
| Sep 29, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -7,588 | $85.01 | $645k | 61,734 | Oct 1, 2025 |
| Sep 30, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +20,000 | $6.89 | $138k | 81,734 | Oct 1, 2025 |
| Sep 30, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $85.06 | $1.7M | 61,734 | Oct 1, 2025 |
| Sep 29, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,588 | $0.00 | $0 | 79,638 | Oct 1, 2025 |
| Sep 30, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 59,638 | Oct 1, 2025 |
| Jul 15, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +5,300 | $18.93 | $100k | 67,034 | Jul 17, 2025 |
| Jul 15, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -2,484 | $82.67 | $205k | 64,550 | Jul 17, 2025 |
| Jul 15, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,888 | $83.87 | $158k | 62,662 | Jul 17, 2025 |
| Jul 15, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -874 | $84.91 | $74k | 61,788 | Jul 17, 2025 |
| Jul 15, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -54 | $85.48 | $4,616 | 61,734 | Jul 17, 2025 |
| Jul 16, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +14,700 | $18.93 | $278k | 76,434 | Jul 17, 2025 |
| Jul 16, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -14,700 | $85.10 | $1.3M | 61,734 | Jul 17, 2025 |
| Jul 15, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,300 | $0.00 | $0 | 81,700 | Jul 17, 2025 |
| Jul 16, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -14,700 | $0.00 | $0 | 67,000 | Jul 17, 2025 |
| Jun 27, 2025 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +20,000 | $18.93 | $379k | 81,734 | Jul 1, 2025 |
| Jun 27, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $80.02 | $1.6M | 61,734 | Jul 1, 2025 |
| Jun 27, 2025 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 87,000 | Jul 1, 2025 |
| Jun 23, 2025 | CBIO CRESCENT BIOPHARMA, INC. | AGrant or award Stock Option (Right to Buy)derivative | +9,023 | $0.00 | $0 | 9,023 | Jun 23, 2025 |
| Jan 6, 2025 | NUVL Nuvalent, Inc. | AGrant or award Class A Common Stock10b5-1 | +18,750 | $0.00 | $0 | 65,750 | Jan 8, 2025 |
| Jan 6, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,152 | $78.28 | $90k | 64,598 | Jan 8, 2025 |
| Jan 6, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -691 | $79.33 | $55k | 63,907 | Jan 8, 2025 |
| Jan 6, 2025 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -2,173 | $80.54 | $175k | 61,734 | Jan 8, 2025 |
| Jan 6, 2025 | NUVL Nuvalent, Inc. | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +37,500 | $0.00 | $0 | 37,500 | Jan 8, 2025 |
| Dec 17, 2024 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock | +4,728 | $1.08 | $5,106 | 38,028 | Dec 18, 2024 |
| Dec 17, 2024 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock | +8,972 | $6.89 | $62k | 47,000 | Dec 18, 2024 |
| Dec 17, 2024 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -4,728 | $0.00 | $0 | 196,156 | Dec 18, 2024 |
| Dec 17, 2024 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -8,972 | $0.00 | $0 | 87,226 | Dec 18, 2024 |
| Nov 29, 2024 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +10,000 | $27.85 | $279k | 43,300 | Dec 3, 2024 |
| Nov 29, 2024 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -8,142 | $95.69 | $779k | 35,158 | Dec 3, 2024 |
| Nov 29, 2024 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,858 | $96.25 | $179k | 33,300 | Dec 3, 2024 |
| Nov 29, 2024 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 84,200 | Dec 3, 2024 |
| Oct 31, 2024 | NUVL Nuvalent, Inc. | MOption exercise Class A Common Stock10b5-1 | +10,000 | $27.85 | $279k | 43,300 | Nov 4, 2024 |
| Oct 31, 2024 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,980 | $88.25 | $175k | 41,320 | Nov 4, 2024 |
| Oct 31, 2024 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -6,320 | $89.17 | $564k | 35,000 | Nov 4, 2024 |
| Oct 31, 2024 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,600 | $90.31 | $144k | 33,400 | Nov 4, 2024 |
| Oct 31, 2024 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -100 | $90.94 | $9,094 | 33,300 | Nov 4, 2024 |
| Oct 31, 2024 | NUVL Nuvalent, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 94,200 | Nov 4, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.